President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
Trump said that the ability to purchase such plans would be “Very, very powerful for our nation and very good for a lot of people.” The order also includes provisions for the creation of health plans that will provide short-term, limited-duration coverage, and for exploration of how employers might use health reimbursement arrangements, which are plans that reimburse employees for medical expense paid for out of pocket.
Senator Rand Paul (R-Kentucky) said that “what I believe is the biggest free market reform of healthcare in a generation” that would “…allow millions of people to get insurance across state lines and at an inexpensive price.” Vice President Mike Pence also praised the executive order, saying that it was a “Critical step to lower the cost of health insurance for working Americans.”
While today’s executive order may not be the full repeal of the Affordable Care Act (ACA) that Republicans have promised their supporters, Trump made it clear that today’s effort was part of a larger push to overhaul healthcare: “I just keep hearing repeal, replace; repeal, replace. Well, we’re starting that process,” he said. “I believe we have the votes to do block grants” at a later time, he went on, apparently referring to a plan similar to the one proposed in the Graham-Cassidy healthcare reform bill that recently failed to garner enough support to move to a Senate vote.
Trump also suggested that the ACA individual market would continue to lose participation from insurers, predicting that half of all counties in the nation would have only 1 insurer participating in the ACA health insurance exchanges, and that others would have none. Allowing associations to purchase insurance plans across states would mean that “they will have so many options,” and that competition among plans would be “staggering.”
The president also indicated that the coming months would see his administration taking further measures related to healthcare and to the economy at large. These measures, he promised, would include “massive” tax cuts.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.